---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Safety questions"
description: "Safety questions on Enhertu (fam-trastuzumab deruxtecan-nxki) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Safety management, and Administration reactions. Questions: What is the Enhertu boxed warning for lung disease and pregnancy? Does Enhertu have contraindications? How is interstitial lung disease (ILD) managed with Enhertu? What should be done if an Enhertu infusion reaction occurs? 4 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/enhertu/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Safety questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)  
Indication pages: [HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)

## Warnings

<a id="enhertu-boxed-warning"></a>

### What is the Enhertu boxed warning for lung disease and pregnancy?

> “WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY
> •	Interstitial Lung Disease (ILD) and pneumonitis, including severe, life-threatening, 
> and fatal cases, have been reported with ENHERTU. Monitor for and promptly 
> investigate signs and symptoms including cough, dyspnea, fever, and other 
> new or worsening respiratory symptoms. Permanently discontinue ENHERTU 
> in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the  
> risk and the need to immediately report symptoms [see Dosage and Administration 
> (2.3), Warnings and Precautions (5.1)].
> •	Embryo-Fetal Toxicity: Exposure to ENHERTU during pregnancy can cause 
> embryo-fetal harm. Advise patients of these risks and the need for effective 
> contraception [see Warnings and Precautions (5.4), Use in Specific 
> Populations (8.1, 8.3)].”

Source: [ENHERTU: Prescribing information, page 2, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=2)

<a id="enhertu-contraindications"></a>

### Does Enhertu have contraindications?

> “Contraindications
>
> None.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Contraindications,None.)

## Safety management

<a id="enhertu-ild-management"></a>

### How is interstitial lung disease (ILD) managed with Enhertu?

> “Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose 1 level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate systemic corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Severe%2C%20life%2Dthreatening%2C%20or%20fatal%20interstitial,for%20at%20least%204%20weeks.)

## Administration reactions

<a id="enhertu-infusion-reactions"></a>

### What should be done if an Enhertu infusion reaction occurs?

> “Slow or interrupt the infusion rate if the patient develops infusion-related symptoms
> Permanently discontinue ENHERTU in case of severe infusion reactions”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=Slow%20or%20interrupt%20the%20infusion,case%20of%20severe%20infusion%20reactions)

> “Other clinically relevant adverse reactions reported in <10% of patients treated with ENHERTU were dizziness (9%), decreased weight (7%), dry eye (7%), dyspnea (6%), blurred vision (5%), abdominal distension (4.8%), pruritus (3.9%), flatulence (2.3%), dehydration (1.6%), febrile neutropenia (1.2%), infusion-related reactions (1.2%), skin hyperpigmentation (0.9%), and gastritis (0.7%)<sup>1</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Other%20clinically%20relevant%20adverse%20reactions,skin%20hyperpigmentation%20%280.9%25%29%2C%20and%20gastritis)

Note: The second passage is from DESTINY-Breast06 (ENHERTU n=434) and includes infusion-related reactions (1.2%).

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): All indications](https://www.evicenter.com/medical-information/enhertu)
- [Indication](https://www.evicenter.com/medical-information/enhertu/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/enhertu/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/enhertu/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/enhertu/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/enhertu/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/enhertu/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu/guidelines)
